Edwards Lifesciences Debt-to-Equity Ratio Growth & History (EW)
Edwards Lifesciences's debt-to-equity ratio was 0.07 for fiscal 2025.
View full Edwards Lifesciences company overviewEdwards Lifesciences annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.07 | −0.00 | −2.54% |
| 2024 | 2024-12-31 | 0.07 | −0.03 | −32.04% |
| 2023 | 2023-12-31 | 0.10 | −0.02 | −13.46% |
| 2022 | 2022-12-31 | 0.12 | 0.00 | +0.65% |
| 2021 | 2021-12-31 | 0.12 | −0.03 | −22.14% |
| 2020 | 2020-12-31 | 0.15 | −0.01 | −7.16% |
| 2019 | 2019-12-31 | 0.16 | −0.03 | −13.46% |
| 2018 | 2018-12-31 | 0.19 | −0.16 | −46.07% |
| 2017 | 2017-12-31 | 0.35 | 0.04 | +11.66% |
| 2016 | 2016-12-31 | 0.31 | 0.08 | +31.67% |
| 2015 | 2015-12-31 | 0.24 | −0.03 | −12.63% |
| 2014 | 2014-12-31 | 0.27 | −0.11 | −28.93% |
| 2013 | 2013-12-31 | 0.38 | 0.26 | +197.63% |
| 2012 | 2012-12-31 | 0.13 | — | — |
| 2009 | 2009-12-31 | 0.08 | — | — |
Edwards Lifesciences quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.07 | −0.00 | −0.43% |
| Q1 2026 | 2026-03-31 | 0.07 | −0.00 | −1.43% |
| Q4 2025 | 2025-12-31 | 0.07 | −0.00 | −2.54% |
| Q3 2025 | 2025-09-30 | 0.07 | −0.01 | −7.31% |
| Q2 2025 | 2025-06-30 | 0.07 | −0.03 | −28.49% |
| Q1 2025 | 2025-03-31 | 0.07 | −0.03 | −29.71% |
| Q4 2024 | 2024-12-31 | 0.07 | −0.03 | −32.04% |
| Q3 2024 | 2024-09-30 | 0.07 | −0.03 | −28.68% |
| Q2 2024 | 2024-06-30 | 0.09 | −0.01 | −13.21% |
| Q1 2024 | 2024-03-31 | 0.10 | −0.02 | −14.62% |
| Q4 2023 | 2023-12-31 | 0.10 | −0.02 | −13.46% |
| Q3 2023 | 2023-09-30 | 0.10 | −0.01 | −6.02% |
| Q2 2023 | 2023-06-30 | 0.11 | −0.01 | −6.55% |
| Q1 2023 | 2023-03-31 | 0.12 | −0.00 | −2.28% |
| Q4 2022 | 2022-12-31 | 0.12 | 0.00 | +0.65% |
| Q3 2022 | 2022-09-30 | 0.11 | −0.01 | −10.53% |
| Q2 2022 | 2022-06-30 | 0.11 | −0.02 | −13.81% |
| Q1 2022 | 2022-03-31 | 0.12 | −0.03 | −20.37% |
| Q4 2021 | 2021-12-31 | 0.12 | −0.03 | −22.14% |
| Q3 2021 | 2021-09-30 | 0.12 | −0.04 | −24.68% |
| Q2 2021 | 2021-06-30 | 0.13 | −0.05 | −25.24% |
| Q1 2021 | 2021-03-31 | 0.15 | −0.03 | −14.57% |
| Q4 2020 | 2020-12-31 | 0.15 | −0.01 | −7.16% |
| Q3 2020 | 2020-09-30 | 0.16 | −0.01 | −6.77% |
| Q2 2020 | 2020-06-30 | 0.18 | −0.01 | −6.61% |
| Q1 2020 | 2020-03-31 | 0.17 | −0.02 | −10.43% |
| Q4 2019 | 2019-12-31 | 0.16 | −0.03 | −13.46% |
| Q3 2019 | 2019-09-30 | 0.18 | −0.18 | −50.48% |
| Q2 2019 | 2019-06-30 | 0.19 | −0.19 | −49.36% |
| Q1 2019 | 2019-03-31 | 0.19 | −0.13 | −40.53% |
| Q4 2018 | 2018-12-31 | 0.19 | −0.16 | −46.07% |
| Q3 2018 | 2018-09-30 | 0.36 | 0.03 | +8.60% |
| Q2 2018 | 2018-06-30 | 0.38 | 0.03 | +9.01% |
| Q1 2018 | 2018-03-31 | 0.32 | 0.02 | +5.10% |
| Q4 2017 | 2017-12-31 | 0.35 | 0.04 | +11.66% |
| Q3 2017 | 2017-09-30 | 0.33 | 0.10 | +46.54% |
| Q2 2017 | 2017-06-30 | 0.35 | 0.10 | +41.87% |
| Q1 2017 | 2017-03-31 | 0.31 | 0.05 | +18.04% |
| Q4 2016 | 2016-12-31 | 0.31 | 0.08 | +31.67% |
| Q3 2016 | 2016-09-30 | 0.22 | −0.03 | −10.68% |
| Q2 2016 | 2016-06-30 | 0.24 | −0.02 | −7.05% |
| Q1 2016 | 2016-03-31 | 0.26 | −0.01 | −3.79% |
| Q4 2015 | 2015-12-31 | 0.24 | −0.03 | −12.63% |
| Q3 2015 | 2015-09-30 | 0.25 | −0.05 | −16.32% |
| Q2 2015 | 2015-06-30 | 0.26 | −0.05 | −16.01% |
| Q1 2015 | 2015-03-31 | 0.27 | −0.27 | −49.68% |
| Q4 2014 | 2014-12-31 | 0.27 | −0.11 | −28.93% |
| Q3 2014 | 2014-09-30 | 0.30 | — | — |
| Q2 2014 | 2014-06-30 | 0.31 | — | — |
| Q1 2014 | 2014-03-31 | 0.54 | — | — |
| Q4 2013 | 2013-12-31 | 0.38 | 0.26 | +197.63% |
| Q4 2012 | 2012-12-31 | 0.13 | — | — |
| Q2 2010 | 2010-06-30 | 0.16 | — | — |
| Q4 2009 | 2009-12-31 | 0.08 | — | — |
Edwards Lifesciences debt-to-equity ratio trends
Over the last five fiscal years, Edwards Lifesciences's debt-to-equity ratio decreased from 0.15 to 0.07, a change of −0.08. The latest reported quarter, Q2 2026, shows 0.07.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edwards Lifesciences source filings ↗